Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL

Abstract: De novo resistance and rapid recurrence often characterize responses of B-cell malignancies to ibrutinib (IBR), indicating a need to develop drug combinations that block compensatory survival signaling and give deeper, more durable responses. To identify such combinations, we previously pe...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	Kallesh D. Jayappa, Craig A. Portell, Vicki L. Gordon, Brian J. Capaldo, Stefan Bekiranov, Mark J. Axelrod, L. Kyle Brett, Julia D. Wulfkuhle, Rosa I. Gallagher, Emanuel F. Petricoin, Timothy P. Bender, Michael E. Williams, Michael J. Weber
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	Elsevier 2017-06-01
Reeks:	Blood Advances
Online toegang:	http://www.sciencedirect.com/science/article/pii/S2473952920302056
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!